Dissecting how SETDB1 and its K867 monoubiquitination drive lung cancer
Official title: Dissecting the Mechanism of SETDB1 and its K867 Monoubiquitination in Lung Cancer Progression
Funded at Roswell Park Cancer Institute Corp · NIH-11378433 · Data updated 2026-11-12
Researchers are studying a specific cancer-related gene mechanism in lung cancer to see how turning on a chemical tag on SETDB1 helps tumors grow.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | August 5, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $402,190 |
| NIH project number | 5R01CA273231-05 |
| Project ID | NIH-11378433 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with non-small cell lung cancer, particularly tumors with KRAS mutations, may benefit from future therapies arising from this research.
✕Less likely to help
Patients whose tumors do not involve SETDB1-driven mechanisms or KRAS-mutant biology may see limited benefit from these findings.
What this research studies
This project looks at how SETDB1 and a particular modification (K867 monoubiquitination) influence the progression of non-small cell lung cancer, especially in tumors with KRAS mutations. Using cellular and molecular techniques, scientists will map the epigenetic changes and transcription programs driven by SETDB1 in KRAS-mutant NSCLC. The work aims to identify possible targets for new therapies that could slow or stop tumor growth. Findings could help patients with NSCLC by guiding future treatments tailored to their tumor’s epigenetic profile.
Why it matters
Potential benefit: It could lead to new ways to treat NSCLC by targeting epigenetic mechanisms.
How similar studies have gone: Previous research shows epigenetic regulators like SETDB1 can influence cancer progression, supporting potential for advancing therapies.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Fang, Jia — Roswell Park Cancer Institute Corp
- Study coordinator: Fang, Jia
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.